<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">Ann Intensive Care</journal-id><journal-title-group><journal-title>Annals of Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2110-5820</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410507</article-id><article-id pub-id-type="pmc">PMC12102009</article-id>
<article-id pub-id-type="publisher-id">1487</article-id><article-id pub-id-type="doi">10.1186/s13613-025-01487-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Response letter to &#x0201c;Confounding by indication and exposure misclassification may undermine corticosteroid effect estimates in ICU patients with alcohol-related hepatitis&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dumas</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gasperment</surname><given-names>Maxime</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2955-0183</contrib-id><name><surname>Ait-Oufella</surname><given-names>Hafid</given-names></name><address><email>hafid.aitoufella@aphp.fr</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rx3b187</institution-id><institution-id institution-id-type="GRID">grid.450307.5</institution-id><institution>Universit&#x000e9; Grenoble Alpes, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041rhpw39</institution-id><institution-id institution-id-type="GRID">grid.410529.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0792 4829</institution-id><institution>Service de M&#x000e9;decine Intensive R&#x000e9;animation - CHU Grenoble Alpes, </institution></institution-wrap>Grenoble, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01875pg84</institution-id><institution-id institution-id-type="GRID">grid.412370.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1100</institution-id><institution>3- Service de M&#x000e9;decine Intensive R&#x000e9;animation, </institution><institution>Assistance Publique - H&#x000f4;pitaux de Paris (AP-HP), H&#x000f4;pital Saint-Antoine, </institution></institution-wrap>184 Rue du Faubourg Saint-Antoine, Paris Cedex 12, 75571 France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02en5vm52</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution>Sorbonne Universit&#x000e9;, </institution></institution-wrap>Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>70</elocation-id><history><date date-type="received"><day>2</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; La Soci&#x000e9;t&#x000e9; de R&#x000e9;animation de Langue Francaise = The French Society of Intensive Care (SRLF) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">To the Editor:</p><p id="Par2">We thank Drs Mao and Li [<xref ref-type="bibr" rid="CR1">1</xref>]. for their interest in our study [<xref ref-type="bibr" rid="CR2">2</xref>]. In their comment, Drs Mao and Li highlight certain methodological points that could have affected the estimation of the effect of corticosteroids on the prognosis of patients with severe alcohol related hepatitis. They correctly point out the difficulties of making causal inferences from real-world data, and we fully agree that our findings cannot be understood as a plea against using corticosteroids in this situation.</p><p id="Par3">However, we would like to offer additional perspective to enhance the interpretation of our findings. The main objective of this work was to describe the clinical picture of patients admitted to the intensive care unit with a diagnosis of alcohol related hepatitis, for which little data is available, and not to evaluate the benefit of corticosteroids use in severe alcohol related hepatitis, for which it remains a recommended treatment, although the target population is still poorly defined [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In this regard, our study emphasizes the wide diversity of clinical trajectories and the heterogeneity of reasons for ICU admission in these patients.</p><p id="Par4">Regarding the analysis of corticosteroids effect, while we did not frame our study as an emulated target trial (which typically requires a large patient sample), we adhered to several guidelines to account for the biases inherent to observational and retrospective data [<xref ref-type="bibr" rid="CR5">5</xref>]. First, we included only patients with a Maddrey score&#x02009;&#x02265;&#x02009;32 and a MELD score&#x02009;&#x02265;&#x02009;20, which are the thresholds commonly used in clinical trials. Second, to limit survivorship bias, only patients at risk who received steroids no more than 3 days prior to ICU admission were retained in the final analysis. Last, all potential confounders previously described in the literature (including patient severity and ongoing infection) were included in the propensity score. Although treatment assignment in ICU settings is rarely random and the assumption of strong ignorability may not hold, we believe we have minimized these pitfalls. To evaluate if this estimate is potentially biased by unmeasured confounding, we applied the E-value, which we estimated at 1.40. Therefore, an unmeasured confounder would need a hazard ratio of at least 1.40 with both corticosteroids use and survival to explain the observed hazard ratio of 1.13 [<xref ref-type="bibr" rid="CR6">6</xref>]. Interestingly, in the subgroup of patients who underwent a liver biopsy, the estimated E-value for the hazard ratio was 4.87, suggesting a robust association. Finally, we found that corticosteroids responders according to Lille score had significantly better survival, which advocates for the use of this medication in these patients, but with an early evaluation of treatment response.</p><p id="Par5">Thus, from our point of view, our data should not be interpreted as an advocacy against corticosteroids use but highlight two important findings, namely the likely difficulties in establishing a definitive diagnosis of alcohol related hepatitis based solely on clinical criteria in this population (which often presents with multiple intertwined causes of organ dysfunction), and the necessity to better identify those who could benefit the most from this treatment. Liver biopsy could provide valuable assistance in this challenging context.</p></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Conflicts</title><p id="Par6">No conflicts to report.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Mao D, Li M. Confounding by indication and exposure misclassification May undermine corticosteroid effect estimates in ICU patients with Alcohol-Related hepatitis. Ann Intensive Care; 2025.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gasperment</surname><given-names>M</given-names></name><name><surname>Duhaut</surname><given-names>L</given-names></name><name><surname>Terzi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Alcohol related hepatitis in intensive care units: clinical and biological spectrum and mortality risk factors: a multicenter retrospective study</article-title><source>Ann Intensive Care</source><year>2025</year><volume>15</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s13613-025-01450-2</pub-id><pub-id pub-id-type="pmid">40229464</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gasperment M, Duhaut L, Terzi N, et al. Alcohol related hepatitis in intensive care units: clinical and biological spectrum and mortality risk factors: a multicenter retrospective study. Ann Intensive Care. 2025;15:53. 10.1186/s13613-025-01450-2.<pub-id pub-id-type="pmid">40229464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Bataller</surname><given-names>R</given-names></name><name><surname>Arab</surname><given-names>JP</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name></person-group><article-title>Alcohol-Associated hepatitis</article-title><source>N Engl J Med</source><year>2022</year><volume>387</volume><fpage>2436</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2207599</pub-id><pub-id pub-id-type="pmid">36577100</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bataller R, Arab JP, Shah VH. Alcohol-Associated hepatitis. N Engl J Med. 2022;387:2436&#x02013;48. 10.1056/NEJMra2207599.<pub-id pub-id-type="pmid">36577100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>A</given-names></name><name><surname>Thursz</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with Pentoxifylline or Placebo&#x02014;a Meta-analysis of individual data from controlled trials</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><fpage>458</fpage><lpage>e4688</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.011</pub-id><pub-id pub-id-type="pmid">29738698</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with Pentoxifylline or Placebo&#x02014;a Meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155:458&#x02013;e4688. 10.1053/j.gastro.2018.05.011.<pub-id pub-id-type="pmid">29738698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;n</surname><given-names>MA</given-names></name><name><surname>Robins</surname><given-names>JM</given-names></name></person-group><article-title>Using big data to emulate a target trial when a randomized trial is not available</article-title><source>Am J Epidemiol</source><year>2016</year><volume>183</volume><fpage>758</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/aje/kwv254</pub-id><pub-id pub-id-type="pmid">26994063</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hern&#x000e1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758&#x02013;64. 10.1093/aje/kwv254.<pub-id pub-id-type="pmid">26994063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Gaster</surname><given-names>T</given-names></name><name><surname>Eggertsen</surname><given-names>CM</given-names></name><name><surname>St&#x000f8;vring</surname><given-names>H</given-names></name><etal/></person-group><article-title>Quantifying the impact of unmeasured confounding in observational studies with the E value</article-title><source>BMJ Med</source><year>2023</year><pub-id pub-id-type="doi">10.1136/bmjmed-2022-000366</pub-id><pub-id pub-id-type="pmid">37159620</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gaster T, Eggertsen CM, St&#x000f8;vring H, et al. Quantifying the impact of unmeasured confounding in observational studies with the E value. BMJ Med. 2023. 10.1136/bmjmed-2022-000366. 2:.<pub-id pub-id-type="pmid">37159620</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>